Skip to main content
Eli Lilly and Company

Scientific Director - Synthetic Process Chemistry

1d

Eli Lilly and Company

Indianapolis, US · Full-time · $148,500 – $257,400

About this role

At Lilly, the Synthetic Molecule Design and Development organization develops synthetic drug substances from pre-clinical through commercialization. Scientists advance portfolios that include small molecules, synthetic peptides, and oligonucleotides to deliver next-generation medicines.

Join the process chemistry team supporting Mounjaro and Zepbound while shaping future programs such as retatrutide. The role centers on traditional Liquid Phase Peptide Synthesis using fragment condensation chemistry to manufacture complex peptides at global scale.

This hands-on position requires bench-level work in LPPS and condensation chemistry alongside a team of chemists, analysts, and engineers. Collaboration spans partners across the United States, Asia, and Europe in a dynamic cross-functional environment.

Technology developed here transfers directly into Lilly’s Medicines Foundry, a new manufacturing facility in Lebanon, Indiana. The role offers end-to-end impact from laboratory development through commercial production with a focus on sustainable process design.

Requirements

  • Expertise in synthetic process chemistry with focus on peptides and small molecules.
  • Proven experience leading peptide commercialization projects using Liquid Phase Peptide Synthesis.
  • Demonstrated ability to work at the bench while directing laboratory and process development activities.
  • Strong background in sustainable chemistry practices including Process Mass Intensity reduction.
  • Experience coordinating technology transfer across internal sites and external manufacturing partners.

Responsibilities

  • Serve as a hands-on scientific leader conducting bench-level LPPS and condensation chemistry development while mentoring a team of peptide chemists.
  • Lead internal technology development and coordinate transfer of early-phase processes to Lilly’s Medicines Foundry for Phase 1 and 2 clinical supply.
  • Collaborate with internal and external manufacturing groups to transfer late-phase processes for validation at internal facilities or external CMO partners.
  • Design synthetic routes and optimize condensation chemistry to reduce Process Mass Intensity and eliminate hazardous reagents.
  • Champion greener process design at every stage and publish green chemistry innovations through industry initiatives.